Tumor Necrosis Factor $\alpha$ (TNF-$\alpha$)-induced Cell Adhesion to Human Endothelial Cells Is under Dominant Control of One TNF Receptor Type, TNF-R55

By Fabienne Mackay, Hansruedi Loetscher, Dietrich Stueber, Gisela Gehr, and Werner Lesslauer

Summary

Tumor necrosis factor $\alpha$ (TNF-$\alpha$) is a pleiotropic cytokine triggering cell responses through two distinct membrane receptors. Stimulation of leukocyte adhesion to the endothelium is one of the many TNF-$\alpha$ activities and is explained by the upregulation of adhesion molecules on the endothelial cell surface. Human umbilical vein endothelial cells (HUVEC) were isolated, cultured, and demonstrated to express both TNF receptor types, TNF-R55 and TNF-R75. Cell adhesion to HUVEC was studied using the HL60, U937, and MOLT-4 cell lines. HUVEC were activated by either TNF-$\alpha$, binding to both TNF-R55 and TNF-R75, and by receptor type-specific agonists, binding exclusively to TNF-R55 or to TNF-R75. The TNF-$\alpha$-induced cell adhesion to HUVEC was found to be controlled almost exclusively by TNF-R55. This finding correlated with the exclusive activity of TNF-R55 in the TNF-$\alpha$-dependent regulation of the expression of the intercellular adhesion molecule type 1 (ICAM-1), E-selectin, and vascular cell adhesion molecule type 1 (VCAM-1). The CD44 adhesion molecule in HUVEC was also found to be upregulated through TNF-R55. However, both TNF-R55 and TNF-R75 upregulate $\alpha$2 integrin expression in HUVEC. The predominant role of TNF-R55 in TNF-$\alpha$-induced adhesion in HUVEC may correlate with its specific control of NF-$\kappa$B activation, since $\kappa$B elements are known to be present in ICAM-1, E-selectin, and VCAM-1 gene regulatory sequences.
human keratinocytes was sufficient to mediate ICAM-1 expression (31), and TNF-R55 was reported to control NF-κB activation in hematopoietic cell lines (23, 32, 33). Less is known about the specific function of TNF-R75. It was found to mediate mouse thymocyte proliferation (34). A recent report provides evidence that TNF-R75 induces GM-CSF secretion in PC60 cell transfectants (35). TNF-R75 was also described to stimulate human fibroblast, mononuclear cell, and NK cell proliferation (28, 36, 37).

Here we describe the activities of the two TNF receptor types in the induction of cell adhesion to human endothelial cells. We report a specific role of TNF-R55 in the induction of cellular adhesion to endothelium. ICAM-1, E-selectin, VCAM-1, and CD44 are induced through TNF-R55, but not through TNF-R75. In contrast, the expression of α2 integrin was found to be mediated through TNF-R75 and TNF-R55.

**Materials and Methods**

**Cell Lines.** HL60, U937, and MOLT-4 cell lines were obtained from the American Type Culture Collection (Rockville, MD). Media and usual culture reagents were purchased from Gibco Laboratories (Grand Island, NY). HL60 and U937 cells were cultured in RPMI 1640, 10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. MOLT-4 cells were cultured in Iscove medium, 10% FCS, 2 mM glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 mM 2-ME (Fluka Chemie AG, Buchs, Switzerland).

**Human Umbilical Vein Endothelial Cells (HUVEC).** HUVEC were purified from human umbilical cords as described by Jaffe et al. (38). HUVEC were cultured in medium M199 (Sigma Chemical Co., St. Louis, MO) supplemented with 20% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, 2.5 μg/ml fungizone (Gibco Laboratories), 20 μg/ml gentamycine (Gibco Laboratories), 100 μg/ml endothelial cell growth factor (ECGF; Collaborative Research, Inotech AG, Dottikon, Switzerland), and 100 μg/ml heparin sodium salt (Sigma Chemical Co.). Culture flasks were precoated for 1 h at ambient temperature with 1% BSA (Sigma Chemical Co.) in PBS, then washed once with HBSS (Gibco Laboratories), 100 μg/ml endothelial cell growth factor (ECGF; Collaborative Research, Inotech AG, Dottikon, Switzerland), and 100 μg/ml heparin sodium salt (Sigma Chemical Co.). Culture flasks were precoated for 1 h at ambient temperature with 1% BSA (Sigma Chemical Co.). Culture flasks were precoated for 1 h at ambient temperature with 1% BSA (Sigma Chemical Co.). Culture flasks were precoated for 1 h at ambient temperature with 1% BSA (Sigma Chemical Co.).

**Reagents.** Mouse mAbs to TNF-R55 (htr-9, htr-5, htr-1, htr-20) and to TNF-R75 (htr-1) have been described previously (26, 39). IgG antibodies were purified from hybridoma supernatants on a protein G-Sepharose column (Pharmacia LKB Biotechnology, Uppsala, Sweden). IgM antibodies were purified by affinity chromatography using goat anti-mouse Ig (μ chain specific) covalently attached to cyanogen bromide-activated agarose beads (Sigma Chemical Co.). Mouse anti-human ICAM-1, anti-human VCAM-1, and anti-human E-selectin were purchased from British Biotechnology Products Ltd. (Oxon, UK). Mouse anti-human MHC class I from Immunotech SA, mouse anti-human CD44 (F10-44-2) from Serotec (Inotech AG), and mouse anti-human integrin molecule antibodies from Telios Pharmaceuticals Inc. (San Diego, CA). Polyclonal anti-TNF receptor antibodies were raised by immunizing rabbits with recombinant extracellular regions of human TNF-R75 or TNF-R55 expressed in the SF9/baculovirus system or CHO cells as previously described (22). Specific antibodies against TNF-R75 or TNF-R55 were purified from rabbit antiserum by affinity chromatography using CNBr-activated Sepharose 4B (Pharmacia LKB Biotechnology) coupled with recombinant soluble TNF-R75 or TNF-R55, respectively. The resulting affinity-purified rabbit antibodies were termed RaTNF-R75 (anti-TNF-R75) and RaTNF-R55 (anti-TNF-R55). Goat anti-mouse Ig antibodies labeled with PE were purchased from Southern Biotechnology Associates Inc. (Birmingham, AL). Recombinant human TNF-α and TNF-α with point mutations at residues 32 and 86, R32W/S86FTNF-α (termed Trp32 Thr86 TNF), purified from Escherichia coli (Loetscher, H., D. Stueber, D. Banner, F. Mackay, and W. Lesslauer, manuscript in preparation).

**Western Blotting Analysis.** HL60 cells and HUVEC were grown to 90% confluency (10^6 cells total) and incubated for 2 h in medium at 4°C with 15 μg/ml of htr or utr mAbs. HL60 cells were then harvested and washed twice with PBS. HUVEC were detached with trypsin-EDTA under conditions described below (see flow cytometry section), and washed twice in PBS supplemented with 100 U/ml aprotinin, 10 mM benzamidine (Sigma Chemical Co.), 1 mM orthophenanthroline (Fluka Chemie AG), 5 μM leupeptin (Fluka Chemie AG), 1 μM pepstatine (Fluka Chemie AG), and 0.1% sodium azide (lysis buffer). 0.75 ml of lysis buffer containing 2% Triton X-100 were added and cells were gently agitated 90 min at 4°C. The lysate was centrifuged 15 min, 70,000 rpm at 4°C in an ultracentrifuge (TL 100; Beckman Instruments, Inc., Fullerton, CA). The supernatant was filtered through a 0.2-μl filter (Acrodisc, Gelman Sciences, Ann Arbor, MI) and incubated 1 h at 4°C under gentle agitation with 50 μl of protein G-Sepharose FF beads (Pharmacia LKB Biotechnology). The beads were washed sequentially with lysis buffer containing 1% and 0.1% Triton X-100, respectively, and transferred to an ultrafilter unit (Millipore Products Division, Bedford, MA) to drain the buffer. The beads were resuspended in 20 μl of Laemmli sample buffer (40), heated for 2 min at 95°C, and centrifuged briefly, and the supernatants subjected to SDS-PAGE. The proteins were transferred to Immobilon-P membranes (Millipore Products Division) and incubated with 20 μg/ml of RaTNF-R75 or RaTNF-R55, respectively, in 50 mM Tris- HCl, pH 7.4, 140 mM NaCl, 5 mM EDTA, 0.02% NaN₃, and 1% dry milk powder at ambient temperature over night, washed, and incubated with 125I-labeled goat anti-rabbit antisemur (New England Nuclear, Boston, MA) for 3 h at ambient temperature. The membranes were then repeatedly washed with PBS, dried, and exposed to an autoradiographic film.

**Flow Cytometry.** HUVEC were detached with trypsin-EDTA (Gibco Laboratories) according to the detached calibrated protocol. When 80% of the cells were detached, the trypsin treatment was stopped with 10 volumes of medium containing 20% FCS, and the cells were washed twice with PBS, 0.05% NaN₃, 1% BSA (FACS buffer [Becton Dickinson & Co., Mountain View, CA]). Cells were incubated 30 min on ice with the respective antibodies at 2 μg/ml in FACS buffer, washed once in FACS buffer, and incubated 30 min on ice with PE-conjugated goat anti-mouse Ig at 5 μg/ml in FACS buffer. Cells were then washed twice with FACS buffer and analyzed on a FACSScan cytofluorimeter (Becton Dickinson & Co.). Cells were gated using forward vs. side scatter to exclude dead cells and debris.

**Cell Adhesion Assay.** 100 μl of a HUVEC suspension (2.5–3 x 10⁶ cells/ml) was seeded in a microtiter plate (MTP; Costar Corp., Cambridge, MA) in the presence of different concentrations of TNF-α, antibodies, or Trp32 Thr86 TNF. The MTP was in-
both receptor types, TNF-R75 and TNF-R55. The level of binding sites per cell (39). The expression of both receptors was relatively low, as revealed by the parallel staining of U937 cells, which express both types.

To investigate whether either or both TNF receptors control the expression of these cell adhesion molecules, HUVEC were incubated with RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine. The cells to be used for adherence were prelabeled overnight with 1 µCi/10⁶ cells of methyl-[³²P]thymidine (Amersham, Amersham, England), washed twice in medium, and added to the endothelial cells in 100 µl medium per well (1-5 × 10⁶ cells/ml). The MTP was further incubated from 30 min to 2 h at 37°C. Nonadherent cells were removed using a calibrated centrifugation of the inverted MTP in PBS at 50 g for 5 min at ambient temperature (41). Radioactively labeled cells specifically bound to the HUVEC were harvested with cell harvester (LKB Instruments, Inc., Gaithersburg, MD). The radioactivity was measured in a Betaplate liquid scintillation counter (Pharmacia LKB Biotechnology). Data are expressed as mean and standard deviation of triplicates.

**Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA).** Nuclear extracts were prepared as described by Dignan et al. (42) with minor modifications. Briefly, cells were harvested and washed twice with PBS. 15–20 × 10⁶ cells were resuspended in a hypotonic lysis buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl₂, 10 mM KCl; buffer A) at 4°C. After a 20-min incubation on ice, cells were homogenized by 20 strokes with a loose-fitting Dounce homogenizer. Nuclei were collected by centrifugation (4 min, 6,500 rpm, 4°C) and nuclear proteins were extracted with three pellet volumes of high salt buffer (20 mM Hepes, pH 7.9, 25% [vol/vol] glycerol, 0.42 M NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, pH 7.5; buffer B). After a 1-h incubation on ice, samples were centrifuged (5 min, 6,500 rpm, 4°C) and the supernatants were diluted in 3 vol low salt buffer (20 mM Hepes, pH 7.9, 20% [vol/vol] glycerol, 0.1 M KCl, 0.2 mM EDTA, pH 7.5, 1% NP-40; buffer C). The samples were used immediately in EMSA or stored at −80°C. Immediately before use, buffers A, B, and C were supplemented with 1% of a 1 M 1,4-dithio-DL-threitol (DTT; Fluka Chemie AG). For EMSA, a synthetic oligonucleotide containing the NF-κB binding site was used as a probe (5'CTCAACAGAGGGACTTCGGAGGCCATCT3'). A corresponding mutated oligonucleotide was included as control in the assay (5CTCAACAGAGGGACTTCGAGAGGCCATCT3'). The expression of both TNF receptor types by HUVEC

**Results**

**TNF Receptor Expression on HUVEC.** The expression of the two TNF receptor types, TNF-R55 and TNF-R75, by HUVEC was investigated first by flow cytometry, using the htr and utr series of mAbs, respectively (26, 39). The analysis was performed at a stage when cultures were 90% confluent after the second passage. The cells were detached by trypsin-EDTA treatment, which had been shown in separate experiments not to detectably affect the surface proteins of the HUVEC. Control experiments showed that the cells analyzed were entirely Von Willebrand factor positive, which confirmed identity and homogeneity of the HUVEC culture. Fig. 1 A shows that unstimulated HUVEC expressed both receptor types, TNF-R75 and TNF-R55. The level of expression of both receptors was relatively low, as revealed by the parallel staining of U937 cells, which express both TNF receptor types with a total of a few thousand TNF binding sites per cell (39).

**Figure 1.** TNF receptor expression on HUVEC and U937 cells. (A) Cytofluorimetric analysis of HUVEC and U937 cells stained with anti-TNF-R55 mAbs htr-5 (·····), htr-1 (-----), and anti-TNF-R75 mAb utr-1 (-----) followed by PE-conjugated goat anti-mouse Ig. An irrelevant mAb was used as negative control (---). (B) Western blot analysis of TNF receptor expression by HUVEC and HL60 cells. Cells were incubated with the respective utr and htr mAb and solubilized by detergent. Immune complexes were purified with protein G from the cell lysate, subjected to electrophoresis on nonreducing SDS-PAGE (12% gel) and transferred to filter membranes. The utr (right) and htr blots (left) were treated with RA TNF-R75 and RA TNF-R55, respectively, followed with 125I-labeled goat anti-rabbit antibody and exposed to x-ray film. Specific receptor bands in the autoradiogram are indicated with arrows. The contaminating lower molecular mass band is due to protein G.

The expression of both TNF receptor types by HUVEC was confirmed using the Western blot technique (Fig. 1 B). Unstimulated HUVEC were incubated for 2 h with either htr-20 (anti-TNF-R55) or utr-1 (anti-TNF-R75) antibodies, detached, and solubilized by detergents. Immune complexes were precipitated with protein G-Sepharose beads and subjected to SDS-PAGE. After electrophoresis, the separated proteins were transferred to filter membranes, which were then incubated with affinity-purified polyclonal rabbit antibodies to TNF-R75 (RatTNF-R75) and to TNF-R55 (RatTNF-R55). After washing, the filters were incubated with 125I-labeled goat anti-rabbit Ig and reactive bands were revealed by autoradiography (Fig. 1 B). The specific bands representing TNF-R75 and TNF-R55 of HUVEC were found comigrating with similar bands from HL60 cells, which are known to express both TNF receptor types (26, 39) (Fig. 1 B).
stimulated from 0 to 10 h with human TNF-α binding to both receptor types, and with receptor type–specific agonists. The specific activation of TNF-R55 was achieved using three independent reagents: first the agonistic mAb htr-1, second the RaTNF-R55 agonistic antibodies, and third a recombinant mutant of human TNF-α, R32W/S86F/TNF-α (Trp32 Thr86 TNF), which binds exclusively to TNF-R55. TNF-R75 activation was achieved with RaTNF-R75 agonistic antibodies. To investigate ICAM-1, E-selectin, and VCAM-1 expression, HUVEC, activated by the various agents, were detached, immunostained, and analyzed by cytofluorimetry. The cytofluorimetric histograms obtained are shown in Fig. 2. Similar to previous reports (45), ICAM-1 was found to be expressed on unstimulated HUVEC at relatively high levels, whereas E-selectin and VCAM-1 were essentially absent. Stimulation of HUVEC with human TNF-α triggered the upregulation of ICAM-1 and the induction of E-selectin and VCAM-1 expression (Fig. 2). The modulation of ICAM-1 and VCAM-1 expression was detectable after 2 h of TNF-α stimulation and reached a sustained maximum level after 6–8 h, contrasting with the expression of E-selectin where induction was maximal 2 h after stimulation and the expression again had declined after 10 h. This confirmed a previous report showing a transient induction of E-selectin by TNF-α (15). The upregulation of ICAM-1 and the induction of VCAM-1 in magnitude and kinetic response were essentially the same, when HUVEC were stimulated through TNF-R55 with Trp32 Thr86 TNF or with htr-1 antibodies (Fig. 2), and similar results were also obtained with the RaTNF-R55 antibodies. Minor differences between the different agonists in the extent of induction were seen, and these might be attributed to experimental variation, but it cannot be excluded that the dimeric or trimeric nature of the different ligands may also play a role (27). In contrast, stimulation via TNF-R75 did not lead to any induction in expression of E-selectin and VCAM-1, nor to upregulation of ICAM-1 expression, even under conditions where RaTNF-R75 antibodies in other functional responses of HUVEC displayed full agonistic activity (see below).

TNF-α–induced CD44 Expression Is under TNF-R55 Control. To study the activity of TNF-α on CD44 expression by the endothelium, HUVEC cultures were first stimulated with TNF-α for various time periods, detached as described above, and immunostained with the mouse mAb F10-44-2 directed to a constant epitope of human CD44 (46). The cytofluorimetric histograms obtained are shown in Fig. 3A.

![Figure 2. Cytofluorimetric profiles of ICAM-1, E-selectin, and VCAM-1 expression on HUVEC. HUVEC were stimulated in culture for 2, 4, 6, and 10 h with 10 ng/ml TNF-α, 10 ng/ml Trp32 Thr86 TNF, 10 μg/ml htr-1, and 1 μg/ml RaTNF-R75 as indicated. HUVEC were then stained for cytofluorimetry with anti–human ICAM-1, anti–human E-selectin, and anti–human VCAM-1 mAbs, followed by PE-conjugated goat anti–mouse Ig. Relative cell numbers (vertical) and fluorescence intensity on logarithmic scale (horizontal) are presented. (NC) Negative control; (unst) unstimulated cells.](image-url)
CD44 and MHC class I expression in unstimulated and activated HUVEC. HUVEC were stimulated 6, 24, 48, and 72 h in culture with 10 ng/ml TNF-α, washed, stained with anti-human CD44 mAb (A), or anti-human MHC class I mAb (B), followed by PE-conjugated goat anti-mouse Ig. HUVEC were also stimulated 72 h with 10 ng/ml Trp32 Thr86 TNF (1), 1 μg/ml RaTNF-R55 (2), 10 μg/ml htr-1 (3), and 1 μg/ml RaTNF-R75 (4), stained as described above with anti-CD44 (C) and anti-MHC class I (D) mAbs. Relative cell numbers (vertical) and fluorescence intensity in logarithmic scale (horizontal) are presented. Unstimulated HUVEC (unst) are in black, stimulated cells in white.

CD44 was found expressed on unstimulated HUVEC in a heterogeneous fashion. The majority of the cells showed no or low CD44 expression, but about a third of the cells showed higher expression. Interestingly, after 48–72 h of TNF-α stimulation, the profile of CD44 expression was significantly changed, since >50% of the cells were shifted to the CD44 highly expressing cell population. As a control, MHC class I expression was analyzed in parallel cultures (Fig. 3 B). MHC class I molecules were expressed on unstimulated HUVEC, and upregulated after 24 h of TNF-α treatment as previously reported (47). It is noteworthy, however, that in contrast to the heterogeneous CD44 staining, the same cells showed homogeneous staining with respect to MHC class I staining (Fig. 3 B). This demonstrates that the wide spectrum of expression levels is a specific property of CD44 and not due to heterogeneity within the HUVEC population. To define the TNF receptor type mediating this CD44 induction, HUVEC were stimulated with predetermined optimal concentrations of the TNF-R55 agonists Trp32 Thr86 TNF, RaTNF-R55, and htr-1, and with the TNF-R75 agonist RaTNF-R75. As shown clearly in Fig. 3 the induction of CD44 (C) as well as the upregulation of MHC class I (D) were mediated exclusively through TNF-R55.

Both TNF Receptors Mediate α2 Integrin Induction. To search for a role of TNF-R75 in adhesion, the integrin family of adhesion molecules was studied. HUVEC were incubated with TNF-α for various periods of time and the expression levels of integrin molecules were analyzed by cytofluorimetry. Some of the integrins, such as α2, α5, α6, αv, β1, and β3, have previously been reported to be expressed on unstimulated HUVEC (48–50). TNF-α stimulated an upregulation of α2 integrin expression (Fig. 4 A). A slight increase of α2 expression was first seen after 24 h of TNF-α stimulation and the expression reached its maximum after 48–72 h. The upregulation of α2 expression is significant and was reproducibly found in three independent experiments. Confirming previous reports, a similar upregulation was not seen with other integrins (51), which indicated that TNF-α-dependent regulation is α2 specific. HUVEC were then stimulated with the receptor type–specific agonists Trp32 Thr86 TNF, RaTNF-R55, htr-1, and with RaTNF-R75. Interestingly, both TNF receptor types were similarly found to mediate α2 induction (Fig. 4, B and C).

HL60 Cell Adhesion on Stimulated HUVEC. Given the different aptitudes of TNF-R75 and TNF-R55 to mediate the induction of the various cell adhesion molecules, we examined whether the two receptor types also differ in their capacity to modulate cell adhesion. HUVEC were stimulated with the various receptor type–specific agonists. HL60 cells that had been prelabeled with methyl-[3H]thymidine were overlayed on the HUVEC for 30 min at 37°C. Nonadherent HL60 cells were removed in a precalibrated centrifugation step and the bound HL60 cells quantitated. In the initial series of studies (Fig. 5) the optimal concentrations of TNF-α, Trp32 Thr86 TNF, RaTNF-R55, htr-1, and RaTNF-R75 needed to achieve adhesion after 6 h of treatment of HUVEC were determined. It was found that the adhesion induced by

Figure 3. Cytofluorimetric profiles of CD44 and MHC class I expression in unstimulated and activated HUVEC. HUVEC were stimulated 6, 24, 48, and 72 h in culture with 10 ng/ml TNF-α, washed, stained with anti–human CD44 mAb (A), or anti–human MHC class I mAb (B), followed by PE-conjugated goat anti–mouse Ig. HUVEC were also stimulated 72 h with 10 ng/ml Trp32 Thr86 TNF (1), 1 μg/ml RaTNF-R55 (2), 10 μg/ml htr-1 (3), and 1 μg/ml RaTNF-R75 (4), stained as described above with anti-CD44 (C) and anti-MHC class I (D) mAbs. Relative cell numbers (vertical) and fluorescence intensity in logarithmic scale (horizontal) are presented. Unstimulated HUVEC (unst) are in black, stimulated cells in white.

Figure 4. Cytofluorimetric profiles of α2 integrin expression in HUVEC. HUVEC were stimulated for various periods of time with 10 ng/ml TNF-α and stained with anti–human α2 integrin mAb, followed by PE-conjugated goat anti–mouse Ig. (A) α2 integrin expression in unstimulated (unst) HUVEC and in HUVEC after 48 and 72 h TNF-α stimulation. (B) HUVEC stimulated 72 h with TNF-R55 agonists Trp32 Thr86 TNF, RaTNF-R55, htr-1, and RaTNF-R75. (C) HUVEC stimulated with TNF-R75 agonist RaTNF-R75 (1 μg/ml). Relative cell numbers (vertical) and fluorescence intensity (logarithmic scale, horizontal) are presented. The bar indicates the position of the control peak.
TNF-α could be mimicked by Trp32 Thr86 TNF despite a small difference in specific activity (Fig. 5 A). These findings were also confirmed when HUVEC were stimulated with RαTNF-R55 and with htr-1 (Fig. 5 B). No significant differences were seen among these TNF-R55 agonists. In contrast, TNF-R75 triggering resulted in little or no induction of adhesion after 6 h stimulation. These findings were confirmed by microscopic inspection of the various cell culture adhesion assays. Similar results were obtained when U937 or MOLT-4 cells were used instead of HL60 cells for the adhesion assays (data not shown).

To investigate the time dependence of the induction of cell adhesion, HUVEC were treated for up to 96 h with the same optimal concentrations of TNF-α, Trp32 Thr86 TNF, RαTNF-R55, htr-1, and RαTNF-R75, and cellular adhesion assays were performed as before with HL60 cells. It was found consistently in three independent experiments (Fig. 6) that a first phase of adhesion occurred within 24 h stimulation when HL60 adhesion was strongly induced through TNF-R55, whereas stimulation through TNF-R75 did not lead to any increased adhesion above background levels. In a later phase, beginning 24 h after the start of cell stimulation, weak adhesion of HL60 cells also was induced. This late adhesion was at a much lower but still significant level. Interestingly, this late adhesion was observed after stimulation through both TNF-R55 and TNF-R75.

Discussion

Among the factors that control the binding of leukocytes to activated endothelium, TNF-α may be one of the most important. The role of TNF-α in cell adhesion has been investigated in a number of studies. For example, melanoma cell adhesion to HUVEC has been reported to be induced by...
Figure 7. NF-κB activation in HUVEC and HL60 cells analyzed by electrophoretic mobility shift assay. (A) HUVEC in culture were stimulated 15 min with 10 ng/ml TNF-α, 10 ng/ml Trp32 Thr86 TNF (MUT:TNF), 10 μg/ml htr-1 mAb, 1 μg/ml RaTNF-R75, 1 μg/ml RaTNF-R55, and 1 μg/ml uαt-1 mAb. Nuclear extracts were incubated 45 min with a 32p-labeled oligonucleotide containing the NF-κB binding site. As control, nuclear extracts were also incubated with a labeled oligonucleotide containing a mutated NF-κB binding site. (B) HL60 cells were incubated 30 min with 5 μg/ml htr-9 mAb, 1 μg/ml RaTNF-K75, 10 and 0.4 nM TNF-α, 10 and 0.4 nM Trp32 Thr86 TNF, and 1 μg/ml RaTNF-R55. Nuclear extracts were incubated 45 min with the same oligonucleotide probes as used for the HUVEC. The specific NF-κB bands are indicated by arrows in the autoradiographs.

NF-κB activation reported in other cell systems (32, 33). The parallel between NF-κB activation and regulation of expression through κB elements suggests that NF-κB might play a critical role in the control of cell adhesion to HUVEC. However, other control mechanisms in addition to the NF-κB pathway must exist, because ICAM-1 is already expressed on unstimulated HUVEC, whereas E-selectin and VCAM-1 appear only after TNF-α stimulation. Moreover, these molecules show different patterns of induction kinetics. E-selectin is very transiently induced, whereas ICAM-1 and VCAM-1 have similar induction kinetics. Additional factors therefore must play a role in the TNF-α signal transduction pathway eliciting adhesion. These factors appear to be under TNF-R55 control, because stimulation through TNF-R55 gives similar expression patterns as those seen after TNF-α treatment interacting with both receptor types.

The adhesion molecules involved in the weak late adhesion found equally after TNF-R55 and TNF-R75 stimulation have not been identified. The integrin adhesion molecules, also called very late antigens (reviewed in reference 63) might be candidates. Previous reports described the regulation of α1, α6, and β3 integrins in HUVEC by TNF-α with or without IFN-γ cooperation (51, 64–66). These responses required a minimum of 24 h of TNF-α exposure and reached a maximal level between 48 and 72 h. The α2 integrin in HUVEC in the present study was reproducibly induced after 48–72 h of TNF-α stimulation. A further parallel induction is provided by the fact that both TNF receptor types similarly mediated the α2 induction and the weak late adhesion, and integrins thus might be envisioned to play a role in late adhesion. However, while α2 associated with the β1 integrin is known to bind to collagen and laminin (63), its role
on the endothelial cell surface is unclear. Furthermore, in a recent study, α2 mRNA and protein in human endothelial cells were found not to be affected by TNF-α (66); the increase in α2 staining upon TNF-α stimulation thus might reflect a change in conformation, or an association with a different cell surface component, leading to an increased reactivity with the antibody rather than a higher expression level. Integrins have been shown, under an appropriate stimulus, to be able to change their conformation (reviewed in reference 63).

Similar to ICAM-1, E-selectin, and VCAM-1, the CD44 adhesion molecule on HUVEC is upregulated after prolonged TNF-α stimulation through TNF-R55. The F10-44-2 antibody (63) used to detect CD44 recognizes a constant part of the various differentially spliced forms of CD44 (67). CD44 is known to be a receptor of several ligands including collagen and hyaluronate. It has been shown to play a role in T cell activation (reviewed in reference 68) and metastatic properties of certain tumor cells (67), but its functional role in endothelial cells is largely unknown. However, the present findings establish distinct activities of TNF-R55 and TNF-R75 in HUVEC and point to a pivotal role of TNF-R55 in TNF-α-induced cell adhesion to the endothelial cell layer, and thus in leukocyte migration and extravasation in sites of inflammation and tissue injury.

We thank Mrs. S. Demmak and B. Wipf for help in construction and expression of Trp32 Thr 86 TNF, Dr. M. Brockhaus for hybridomas, and Dr. C. Mackay for critically reading the manuscript. We thank Mrs. M. Dellenbach for excellent assistance with HUVEC culture.

Address correspondence to Werner Lesslauer, Building 15, Room 6A, F. Hoffmann-La Roche, CH-4002 Basel, Switzerland.

Received for publication 28 December 1992.

References

1. Carswell, E.A., L.J. Old, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin induced serum factor that causes necrosis of tumor. Proc. Natl. Acad. Sci. USA. 72:3666.
2. Old, L. 1986. Tumor necrosis factor. Science (Wash. DC). 230:630.
3. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF: a primary mediator of host response. Annu. Rev. Immunol. 7:625.
4. Vassalli, P. 1992. The Pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411.
5. Pober, J.S., and R.S. Cotran. 1990. Cytokines and endothelial cell biology. Physiol. Rev. 70:427.
6. Mantovani, A., F. Bussolino, and E. Dejana. 1992. Cytokine regulation of endothelial cell function. FASEB (Fed. Am. Soc. Exp. Biol.) J. 6:2591.
7. Dosne, A.M., F. Dubor, F. Lutcher, M. Parant, and L. Chedid. 1988. Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decrease blood fibrinolytic activity in the rat. Thromb Res. 51:115.
8. Nawroth, P.P., I. Bank, D. Handley, J. Castimeris, L. Chees, and D. Stern. 1986. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163:1363.
9. Broudy, V.C., K. Kaushansky, G.M. Segal, J.M. Harlan, and J.W. Adamson. 1986. Tumor necrosis type α stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA. 83:7467.
10. Jirik, F.R., T.J. Podor, T. Hirano, T. Kishimoto, D.J. Loskutoff, D.A. Carson, and M. Lotz. 1989. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J. Immunol. 142:144.
11. Henning, B., S.E. Goldblum, and C.J. McClain. 1987. Interleukin-1 (IL-1) and tumor necrosis factor/cachectin (TNF) increase endothelial permeability in vitro. J. Leukocyte Biol. 42:551.
12. Bevilacqua, M.P., S. Stengelin, M.A. Gimbrone, and B. Seed. 1989. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science (Wash. DC). 243:1160.
13. Pober, J.S., L.A. Lapierre, A.H. Stolpen, T.A. Brock, T.A. Springer, W. Fiers, M.P. Bevilacqua, D.L. Mendrick, and M.A. Gimbrone. 1987. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1. Science (Wash. DC). 230:3319.
14. Osborn, L., C. Hession, R. Tizard, C. Vassallo, S. Luhowskyj, G. Chi-Rosso, and R. Lobb. 1989. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 59:1203.
15. Rice, G.E., and M.P. Bevilacqua. 1989. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science (Wash. DC). 246:1303.
16. Carlos, T.M., B.R. Schwartz, N.L. Kovach, E. Yee, M. Rosso, L. Osborn, G. Chi-Rosso, B. Newman, R. Lobb, and J.M. Harlan. 1990. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood. 76:965.
17. Walz, G., A. Aruffo, W. Kolanus, M. Bevilacqua, and B. Seed. 1990. Recognition by ELAM-1 of the sialyl-Le x determinant on myeloid and tumor cells. Science (Wash. DC). 250:1132.
18. Elices, M.J., L. Osborn, Y. Takada, C. Crouse, S. Luhowskyj, M.E. Hemler, and R.R. Lobb. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/β1 integrin binding site. Cell. 60:577.
19. Marlin, S.D., and T.A. Springer. 1987. Purified intercellular
adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). *Cell.* 51:813.
20. Springer, T.A. 1990. Adhesion receptors of the immune system. *Nature (Lond.)* 346:425.
21. Loetscher, H., M. Brockhaus, Z. Dembic, R. Gentz, U. Gubler, H.P. Hohmann, H.W. Lahm, A.P.G.M. van Loon, Y.C.E. Pan, E.J. Schlaeger, M. Steinmetz, H. Tabuchi, and W. Lesslauer. 1991. Two distinct tumor necrosis factor receptors of members of a new cytokine receptor gene family. In Oxford Surveys on Eukaryotic Genes. N. Maclean, editor. Oxford University Press, Oxford. 119-142.
22. Loetscher, H., R. Gentz, M. Zulauf, A. Lustig, H. Tabuchi, E.J. Schlaeger, M. Brockhaus, H. Holtmann, C. Brakebusch, Y.S. Avni, I. Engelmann, H., H. Tabuchi, and W. Lesslauer. 1991. Recombinant 55 kDa tumor necrosis factor (TNF) receptor. *J. Biol. Chem.* 266:18324.
23. Hohmann, H.P., M. Brockhaus, P.A. Baeuerle, R. Remy, R. Kolbeck, and A.P.G.M. van Loon. 1990. Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-κB. *J. Biol. Chem.* 265:22409.
24. Dembic, Z., H. Loetscher, U. Gubler, Y.C.E. Pan, H.W. Lahm, R. Gentz, M. Brockhaus, and W. Lesslauer. 1990. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. *Cytokine* 2:231.
25. Loetscher, H., M. Steinmetz, and W. Lesslauer. 1991. Tumor necrosis factor: receptors and inhibitors. *Cancer Cells (Cold Spring Harbor).* 3:221.
26. Loetscher, H., E.J. Schlaeger, H.W. Lahm, Y.C.E. Pan, W. Lesslauer, and M. Brockhaus. 1990. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells. *J. Biol. Chem.* 265:20313.
27. Engelmann, H., H. Holtmann, C. Brakebusch, Y.S. Avni, I. Sarow, Y. Nophar, E. Hadas, O. Leitner, and D. Wallach. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. *J. Biol. Chem.* 265:14497.
28. Espevik, T., M. Brockhaus, H. Loetscher, U. Nonstad, and R. Shalaby. 1990. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. *J. Exp. Med.* 171:415.
29. Shalaby, M.R., A. Sundan, H. Loetscher, M. Brockhaus, W. Lesslauer, and T. Espevik. 1990. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. *J. Exp. Med.* 172:1517.
30. Tartaglia, L.A., and D.V. Goeddel. 1992. Tumor necrosis factor receptor signalling. *J. Biol. Chem.* 267:4304.
31. Trefzer, U., M. Brockhaus, H. Loetscher, F. Parlow, A. Kapp, E. Schöpf, and J. Krutmann. 1991. 55-kD tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression. *J. Invest. Dermatol.* 97:911.
32. Krupp, A., B. Thoma, T. Machleidt, K. Wiegmann, and M. Kröneke. 1992. Inhibition of tumor necrosis factor (TNF)-mediated NF-κB activation by selective blockade of the human 55-kDA TNF receptor. *J. Immunol.* 148:3152.
33. Hohmann, H.P., R. Remy, B. Pöschl, and A.P.G.M. van Loon. 1990. Tumor necrosis factors-α and -β bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-κB at low receptor occupancy and within minutes after receptor binding. *J. Biol. Chem.* 265:15183.
34. Tartaglia, L.A., R.F. Weber, I.S. Figari, C. Reynolds, M.A. Palladino, Jr., and D.V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. *Proc. Natl. Acad. Sci. USA.* 88:9292.
35. Vandenabeele, P., W. Declercq, D. Vercammen, M. Van de Craen, J. Grooten, H. Loetscher, M. Brockhaus, W. Lesslauer, and W. Fiers. 1992. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. *J. Exp. Med.* 176:1015.
36. Gehr, G., R. Gentz, M. Brockhaus, H. Loetscher, and W. Lesslauer. 1992. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. *J. Immunol.* 149:911.
37. Naume, B., R. Shalaby, W. Lesslauer, and T. Espevik. 1991. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphocyte-activated killer cell activity and proliferation of natural killer cells. *J. Immunol.* 146:3045.
38. Jaffe, E.A., R.L. Nachman, C.G. Becker, and C.R. Minick. 1973. Culture of human endothelial cells derived from umbilical veins. *J. Clin. Invest.* 52:2745.
39. Brockhaus, M., H.J. Schoenfeld, E.J. Schlaeger, W. Hunziker, W. Lesslauer, and H. Loetscher. 1990. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. *Proc. Natl. Acad. Sci. USA.* 87:3127.
40. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680.
41. Subira, J.L., J. Gil, J.G. Ruiz de Morales, R. Rodriguez, and E.G. De la Concha. 1991. Some improvements in the reversed centrifugation method for the quantification of cell to cell adhesion. *J. Immunol. Methods.* 140:127.
42. Digman, J.D., R.M. Lebowitz, and R.G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.* 11:1475.
43. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. *Cell.* 46:705.
44. Leonardo, M., J.W. Pierce, and D. Baltimore. 1987. Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. *Science (Washington, DC).* 236:1573.
45. Dustin, M.L., R. Rothlein, A.K. Bhan, C.A. Dinarello, and T.A. Springer. 1986. Induction by IL-1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). *J. Immunol.* 137:245.
46. Dalchau, R., J. Kirkley, and J.W. Fabre. 1980. Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W3/13 antigen of the rat. *Eur. J. Immunol.* 10:745.
47. Lapierre, L.A., W. Fiers, and J.S. Pober. 1988. Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. *J. Exp. Med.* 167:794.
48. Conforti, G., A. Zanetti, S. Colella, M. Abbadini, P.C. Marchisio, R. Pyteia, F. Giancotti, G. Tarone, L.R. Languino, and E. Dejana. 1989. Interaction of fibronectin with cultured human endothelial cells: characterization of the specific receptor. *Blood.* 73:1576.
49. Languino, L.R., K.R. Gehlsen, E. Wayne, W.G. Carter, E. Engvall, and E. Ruoslahti. 1989. Endothelial cells use α2β1 integrin as laminin receptor. *J. Cell Biol.* 109:2455.
50. Kramer, R.H., Y.F. Cheng, and R. Clyman. 1990. Human microvascular endothelial cells use β1 and β3 integrin receptor complexes to attach to laminin. *J. Cell Biol.* 111:1233.
51. Delfilippo, P., C. Bozzo, M. Geuna, P. Rossino, L. Silengo, and G. Tarone. 1992. Modulation of extracellular matrix
receptors (integrins) on human endothelial cells by cytokines. In Angiogenesis: Key Principles-Science-Technology-Medicine. R. Steiner, P.B. Weisz, and R. Langer, editors, Birkhauser Verlag, Basel. 193–197.

52. Lowenthal, J.W., D.W. Ballard, E. Böhnlein, and W.C. Greene. 1989. Tumor necrosis factor α induces proteins that bind specifically to κB-like enhancer elements and regulate interleukin 2 receptor α-chain gene expression in primary human T lymphocytes. Proc. Natl. Acad. Sci. USA. 86:2331.

53. Osborn, L., S. Kundel, and G.J. Nabel. 1989. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA. 86:2336.

54. Collins, T. 1992. Analysis of the ELAM-1 and VCAM-1 promoters—tools to target gene expression in endothelium in transgenic animals. J. Vasc. Surg. 15:923.

55. Voraberger, G., R. Schäffer, and C. Stratowa. 1991. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5'-regulatory region. J. Immunol. 145:2777.

56. Montgomery, K.F., L. Osborn, C. Hession, R. Tizard, D. Goff, C. Vassallo, P.I. Tarr, K. Bomskryt, R. Lob, J.M. Harlan, and T.H. Pohlm. 1991. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc. Natl. Acad. Sci. USA. 88:6523.

57. Wawryk, S.O., P.N. Cockerill, I.P. Wicks, and A.W. Boyd. 1991. Isolation and characterization of the promoter region of human intercellular adhesion molecule-1 gene. Int. Immunol. 3:83.

58. Iademarco, M.F., J.J. McQuillan, G.D. Rosen, and D.C. Dean. 1992. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J. Biol. Chem. 267:16323.

59. Israel, A., O. Le Bail, D. Hatat, J. Piette, M. Kieran, F. Logeat, D. Wallach, M. Fellous, and P. Kourilsky. 1989. TNF stimulates expression of mouse MHC class I genes by inducing an NF-κB-like enhancer binding activity which displaces constitutive factors. EMBO (Eur. Mol. Biol. Organ.) J. 8:3793.

60. Shimizu, Y., W. Newman, Y. Tanaka, and S. Shaw. 1992. Lymphocyte interactions with endothelial cells. Immunol. Today. 13:106.

61. Shimizu, Y., W. Newman, T.V. Gopal, K.J. Horgan, N. Graber, L.D. Beall, G.A. van Seventer, and S. Shaw. 1991. Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J. Cell Biol. 113:1203.

62. Thorp, K.M., C. Southern, I.N. Bird, and N. Matthews. 1992. Tumor necrosis factor induction of ELAM-1 and ICAM-1 on human umbilical vein endothelial cells—Analysis of tumor necrosis factor–receptor interactions. Cytokine. 4:313.

63. Hynes, R.O. 1992. Integrins: versatility, modulation, and signalling in cell adhesion. Cell. 69:11.

64. Santala, P., and J. Heino. 1991. Regulation of integrin-type cell adhesion receptors by cytokines. J. Biol. Chem. 266:23505.

65. Defilippi, P., G. Truffa, G. Stefanuto, F. Altruda, M. Silengo, and G. Tarone. 1991. Tumor necrosis factor α and interferon γ modulate the expression of the vitronectin receptor (integrin β3) in human endothelial cells. J. Biol. Chem. 266:7638.

66. Defilippi, P., L. Silengo, and G. Tarone. 1992. αβ integrin (laminin receptor) is down-regulated by tumor necrosis factor α and interleukin-1 β in human endothelial cells. J. Biol. Chem. 267:18303.

67. Gunthert, U., M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Hausmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13.

68. Haynes, B.F., M.J. Telen, L.P. Hale, and S.M. Denning. 1989. CD44-A molecule involved in leukocyte adherence and T-cell activation. Immunol. Today. 10:423.